Notes to Unaudited Condensed Consolidated
Financial Statements
1. Basis of Presentation and Summary of Significant Accounting
Policies
The unaudited condensed consolidated financial
statements of Patriot Scientific Corporation (the “Company”, “PTSC”, “Patriot”, “we”,
“us” or “our”) presented herein have been prepared pursuant to the rules of the Securities and Exchange
Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required
by accounting principles generally accepted in the United States of America. These unaudited condensed consolidated financial statements
should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Report on Form
10-K for our fiscal year ended May 31, 2016.
In the opinion of management, the interim condensed
consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the
results for the interim period presented. Operating results for the three month period ended August 31, 2016 are not necessarily
indicative of the results that may be expected for the year ending May 31, 2017.
Basis of Consolidation
The condensed consolidated balance sheets at
August 31, 2016 and May 31, 2016 and condensed consolidated statements of operations and condensed consolidated statements of cash
flows for the three months ended August 31, 2016 and 2015 include our accounts and those of our inactive subsidiaries: Patriot
Data Solutions Group, Inc. (“PDSG”) which includes Crossflo Systems, Inc. (“Crossflo”), and Plasma Scientific
Corporation. All significant intercompany accounts and transactions have been eliminated.
Liquidity and Management’s Plans
Cash shortfalls currently experienced by Phoenix
Digital Solutions, LLC (“PDS”) will have an adverse effect on our liquidity. To date, we have determined that it is
in the best interests of the Moore Microprocessor Patent (“MMP”) licensing program that we provide our 50% share of
capital to provide for PDS expenses including legal retainers, and litigation related payments in the event license revenues received
by PDS are insufficient to meet these needs. We believe it is likely that contributions to PDS to fund working capital will continue
to be required.
PDS had been incurring significant third-party
costs for expert testimony, depositions and other related litigation costs. We could be required to make capital contributions
to PDS for any future litigation related costs in the event that PDS does not receive sufficient licensing revenues to pay these
expenses.
Our current liquid cash resources as of August
31, 2016, are expected to provide the funds necessary to support our operations through at least the next twelve months. The cash
flows from our interest in PDS represent our only significant source of cash generation. In the event of a continued
decrease or interruption in MMP portfolio licensing we will incur a significant reduction to our cash position. It is highly unlikely
that we would be able to obtain any additional sources of financing to supplement our cash and cash equivalents and short-term
investment position of $2,693,897 at August 31, 2016.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Liquidity and Management’s Plans (continued)
On March 20, 2013, Technology Properties
Limited, Inc. (“TPL”) filed a petition under Chapter 11 of the United States Bankruptcy Code. We have been
appointed to the creditors’ committee and have been closely monitoring the progress in this matter as it relates to our
interest in PDS. A Joint Plan of Reorganization (the “Joint Plan”) between TPL and the creditor’s committee
was confirmed by the Bankruptcy Court on February 11, 2015 with the entered confirmation order becoming final on April
2, 2015. In the event we are required to provide funding to PDS that is not reciprocated by TPL, our ownership
percentage in PDS will increase and we will have a controlling financial interest in PDS, in which case, we will consolidate
PDS in our condensed consolidated financial statements.
Investments in Marketable Securities
We determine the appropriate classification
of our investments at the time of purchase and reevaluate such designation at each balance sheet date. Our investments in marketable
securities have been classified and accounted for as held-to-maturity based on management’s investment intentions relating
to these securities. Held-to-maturity marketable securities are stated at amortized cost. Unrealized gains and losses, net of deferred
taxes, are recorded as a component of other comprehensive income (loss). We follow the authoritative guidance to assess whether
our investments with unrealized loss positions are other than temporarily impaired. Realized gains and losses and declines in fair
value judged to be other than temporary are determined based on the specific identification method and are reported in other income
(expense), net in the condensed consolidated statements of operations.
Investment in Affiliated Company
We have a 50% interest in PDS (see Note 3).
We account for our investment using the equity method of accounting since the investment provides us the ability to exercise significant
influence, but not control, over the investee. Significant influence is generally deemed to exist if we have an ownership interest
in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s
Board of Directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method
of accounting, the investment, originally recorded at cost, is adjusted to recognize our share of net earnings or losses of the
investee and is recognized in the condensed consolidated statements of operations in the caption “Equity in earnings (loss)
of affiliated company” and also is adjusted by contributions to and distributions from PDS.
PDS, as an unconsolidated equity investee,
recognizes revenue from technology license agreements at the time a contract is entered into, the license method is determined
(paid-in-advance or on-going royalty), performance obligations under the license agreement are satisfied, and the realization of
revenue is assured, which is generally upon the receipt of the license proceeds. PDS may at times enter into license agreements
whereby contingent revenues are recognized as one or more contractual milestones are met.
We review our investment in PDS to determine
whether events or changes in circumstances indicate that the carrying amount may not be recoverable. The primary factors we consider
in our determination are the financial condition, operating performance and near term prospects of PDS. If a decline in value
is deemed to be other than temporary, we would recognize an impairment loss.
Earnings (Loss) Per Share
Basic earnings per share includes no dilution
and is computed by dividing earnings available to common stockholders by the weighted average number of common shares outstanding
for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an
entity.
At August 31, 2016 and 2015 potential common
shares of 2,600,000 and 2,760,000, respectively, related to our outstanding options were not included in the calculation of diluted
loss per share as we recorded a loss. Had we reported net income for the three
months ended August 31, 2016 and 2015, no shares of common stock would have been included in the calculation of diluted income
per share using the treasury stock method.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Earnings (Loss) Per Share (continued)
In connection with our acquisition of Crossflo,
which is part of PDSG, we issued escrow shares that are contingent upon certain representations and warranties made by Crossflo
at the time of the merger agreement (see Note 6). We exclude these escrow shares from the basic loss per share calculations and
would have included the escrowed shares in the diluted income per share calculations if we reported net income.
Income Taxes
We follow authoritative guidance in accounting
for uncertainties in income taxes. This authoritative guidance prescribes a recognition threshold and measurement requirement for
the financial statement recognition of a tax position that has been taken or is expected to be taken on a tax return and also provides
guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Under
this guidance we may only recognize tax positions that meet a “more likely than not” threshold.
We follow authoritative guidance to evaluate
whether a valuation allowance should be established against our deferred tax assets based on the consideration of all available
evidence using a “more likely than not” standard. In making such judgments, significant weight is given to evidence
that can be objectively verified. We assess our deferred tax assets annually under more likely than not scenarios in which they
may be realized through future income.
We have determined that it was more likely
than not that all of our deferred tax assets will not be realized in the future due to our continuing pre-tax and taxable losses.
As a result of this determination we have placed a full valuation allowance against our deferred tax assets.
We follow authoritative guidance to adjust
our effective tax rate each quarter to be consistent with the estimated annual effective tax rate. We are also required to record
the tax impact of certain discrete items, unusual or infrequently occurring, including changes in judgment about valuation allowances
and effects of changes in tax laws or rates, in the interim period in which they occur. In addition, jurisdictions with a projected
loss for the year or a year-to-date loss where no tax benefit can be recognized are excluded from the estimated annual effective
tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based
upon the mix and timing of actual earnings or losses versus annual projections.
Assessment of Contingent Liabilities
We are involved in various legal matters, disputes,
and patent infringement claims which arise in the ordinary course of our business. We accrue for any estimated losses at the time
when we can make a reliable estimate of such loss and it is probable that it has been incurred. By their very nature, contingencies
are difficult to estimate. We continually evaluate information related to all contingencies to determine that the basis on which
we have recorded our estimated exposure is appropriate.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Intellectual Property Rights
PDS, our investment in affiliated company,
relies on a combination of patents, trademarks, copyrights, trade secret laws, confidentiality procedures and licensing arrangements
to protect our intellectual property rights. We have seven U.S., nine European, and three Japanese patents all of which expired
between August 2009 and October 4, 2016. These patents, while expired, may have certain retrospective statutory benefits that will
fully diminish six years after the patent expiration dates. The patent useful life for purposes of negotiating licenses is finite
and these patents are subject to legal challenges, which in combination with the limited life, could adversely impact the stream
of revenues. A successful challenge to the ownership of the technology or the proprietary nature of the intellectual property would
materially damage business prospects. Any issued patent may be challenged and invalidated.
Recent Accounting Pronouncements
In August 2014, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, "Presentation of Financial
Statements – Going Concern." ASU 2014-15 provides guidance in generally accepted accounting principles about management’s
responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and
to provide related footnote disclosures. ASU 2014-15 is effective for annual reporting periods ending after December 15, 2016 and
for annual periods and interim periods thereafter (fiscal year 2017 for the Company). Early adoption is permitted. We have not
yet determined the potential effects of the adoption of ASU 2014-15 on our condensed consolidated financial statements.
In August 2016, the FASB issued ASU No. 2016-15,
“Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments.” ASU 2016-15 provides guidance
intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The issue addressed
in ASU 2016-15 that will affect the Company is classifying distributions received from equity method investments. The guidance
provides an accounting policy election for classifying distributions received from equity method investments using either a cumulative
earnings approach or a nature of distributions approach. ASU 2016-15 is effective for financial statements issued for fiscal years
beginning after December 15, 2017, and interim periods within those fiscal years (fiscal 2019 for the Company). Early adoption
is permitted. We have not yet determined the potential effects of the adoption of ASU 2016-15 on our condensed consolidated financial
statements.
2. Cash, Cash Equivalents, Restricted Cash and Marketable Securities
We consider all highly liquid investments acquired
with a maturity of three months or less from the purchase date to be cash equivalents.
Restricted cash and cash equivalents at August
31, 2016 and May 31, 2016 consist of a savings account held as collateral for our corporate credit card account.
At August 31, 2016 and May 31, 2016, our short-term
marketable securities in the amount of $1,706,218 and $1,955,493, respectively, consist of certificates of deposit with various
financial institutions, with maturity dates between three months and twelve months from the purchase date.
At August 31, 2016 and May 31, 2016, our long-term
marketable securities in the amount of $501,196 and $500,409, respectively, consist of certificates of deposit with various financial
institutions, with maturity dates greater than twelve months from the purchase date.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Cash, Cash Equivalents, Restricted Cash
and Marketable Securities (continued)
We follow authoritative guidance to account
for our marketable securities as held-to-maturity. Under this authoritative guidance we are required to maximize the use of observable
inputs and minimize the use of unobservable inputs when measuring fair value. We determine fair value based on quoted prices when
available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates
commensurate with the credit quality and duration of the investment or valuations by third party professionals. The three levels
of inputs that we may use to measure fair value are:
Level 1: Unadjusted quoted prices in active
markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are
not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
and
Level 3: Prices or valuation techniques that
require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market
activity).
The following tables detail the fair value
measurements within the fair value hierarchy of our cash, cash equivalents and investments in marketable securities:
|
|
|
|
Fair
Value Measurements at August 31, 2016 Using
|
|
|
|
|
Quoted Prices
|
|
Significant
|
|
|
|
|
|
|
in Active
|
|
Other
|
|
Significant
|
|
|
Fair Value at
|
|
Markets for
|
|
Observable
|
|
Unobservable
|
|
|
August 31,
|
|
Identical Assets
|
|
Inputs
|
|
Inputs
|
|
|
2016
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
88,948
|
|
|
$
|
88,948
|
|
|
$
|
–
|
|
|
$
|
–
|
|
Money market funds
|
|
|
148,186
|
|
|
|
148,186
|
|
|
|
–
|
|
|
|
–
|
|
Certificates of deposit
|
|
|
750,545
|
|
|
|
–
|
|
|
|
750,545
|
|
|
|
–
|
|
Restricted cash and cash equivalents
|
|
|
21,362
|
|
|
|
21,362
|
|
|
|
–
|
|
|
|
–
|
|
Marketable securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certificates of deposit
|
|
|
1,706,218
|
|
|
|
–
|
|
|
|
1,706,218
|
|
|
|
–
|
|
Long-term:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certificates of deposit
|
|
|
501,196
|
|
|
|
–
|
|
|
|
501,196
|
|
|
|
–
|
|
Total
|
|
$
|
3,216,455
|
|
|
$
|
258,496
|
|
|
$
|
2,957,959
|
|
|
$
|
–
|
|
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Cash, Cash Equivalents, Restricted Cash
and Marketable Securities (continued)
|
|
|
|
Fair Value Measurements at May 31, 2016 Using
|
|
|
|
|
Quoted Prices
|
|
Significant
|
|
|
|
|
|
|
in Active
|
|
Other
|
|
Significant
|
|
|
Fair Value at
|
|
Markets for
|
|
Observable
|
|
Unobservable
|
|
|
May 31,
|
|
Identical Assets
|
|
Inputs
|
|
Inputs
|
|
|
2016
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
113,803
|
|
|
$
|
113,803
|
|
|
$
|
–
|
|
|
$
|
–
|
|
Money market funds
|
|
|
795,600
|
|
|
|
795,600
|
|
|
|
–
|
|
|
|
–
|
|
Certificates of deposit
|
|
|
250,173
|
|
|
|
–
|
|
|
|
250,173
|
|
|
|
–
|
|
Restricted cash and cash equivalents
|
|
|
21,336
|
|
|
|
21,336
|
|
|
|
–
|
|
|
|
–
|
|
Marketable securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certificates of deposit
|
|
|
1,955,493
|
|
|
|
–
|
|
|
|
1,955,493
|
|
|
|
–
|
|
Long-term:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certificates of deposit
|
|
|
500,409
|
|
|
|
–
|
|
|
|
500,409
|
|
|
|
–
|
|
Total
|
|
$
|
3,636,814
|
|
|
$
|
930,739
|
|
|
$
|
2,706,075
|
|
|
$
|
–
|
|
We purchase certificates of deposit with varying
maturity dates. The following table summarizes the purchase date maturities, gross unrealized gains or losses and fair value of
the certificates of deposit as of August 31, 2016:
|
|
August 31, 2016
(Unaudited)
|
|
|
Cost
|
|
Gross Unrealized Gains/(Losses)
|
|
Fair
Value
|
Maturity
|
|
|
|
|
|
|
|
|
|
|
|
|
Due in three months or less
|
|
$
|
750,545
|
|
|
$
|
–
|
|
|
$
|
750,545
|
|
Due in one year or less
|
|
$
|
1,706,218
|
|
|
|
–
|
|
|
$
|
1,706,218
|
|
Due in one year or more
|
|
$
|
501,196
|
|
|
$
|
–
|
|
|
$
|
501,196
|
|
We purchase certificates of deposit with varying
maturity dates. The following table summarizes the purchase date maturities, gross unrealized gains or losses and fair value of
the certificates of deposit as of May 31, 2016:
|
|
May 31, 2016
|
|
|
Cost
|
|
Gross Unrealized Gains/(Losses)
|
|
Fair
Value
|
Maturity
|
|
|
|
|
|
|
|
|
|
|
|
|
Due in three months or less
|
|
$
|
250,173
|
|
|
$
|
–
|
|
|
$
|
250,173
|
|
Due in one year or less
|
|
$
|
1,955,493
|
|
|
$
|
–
|
|
|
$
|
1,955,493
|
|
Due in one year or more
|
|
$
|
500,409
|
|
|
$
|
–
|
|
|
$
|
500,409
|
|
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
3. Investment in Affiliated Company
On June 7, 2005, we entered into a Master Agreement
(the “Master Agreement”) with TPL, and Charles H. Moore (“Moore”), the co-inventor of the technology which
is the subject of the MMP Portfolio of microprocessor patents, pursuant to which the parties resolved all legal disputes between
them. Pursuant to the Master Agreement, we and TPL entered into the Limited Liability Company Operating Agreement of PDS (the “LLC
Agreement”) into which we and Moore contributed our rights to certain of our technologies.
We and TPL each own 50% of the membership interests
of PDS, and each member has the right to appoint one member of the three member management committee. The two appointees are required
to select a mutually acceptable third member of the management committee. There had not been a third management committee member
since May 2010; however, as a result of our initiation of arbitration seeking the appointment of a third member, on December 16,
2014, an independent manager to the PDS management committee was selected by the arbitrator. Pursuant to the LLC Agreement, we
and TPL initially agreed to establish a working capital fund for PDS of $4,000,000, of which our contribution was $2,000,000. The
working capital fund was increased to a maximum of $8,000,000 as license revenues are achieved. We and TPL are obligated to fund
future working capital requirements at the discretion of the management committee of PDS in order to maintain working capital of
not more than $8,000,000. If the management committee determines that additional capital is required, neither we nor TPL are required
to contribute more than $2,000,000 in any fiscal year. No such contributions were made during the three months ended August 31,
2016 and 2015. Distributable cash and allocation of profits and losses have been allocated to the members in the priority defined
in the LLC Agreement.
On July 11, 2012, we entered into the Program
Agreement with PDS, TPL, and Alliacense, and an Agreement (the “TPL Agreement”) with TPL. Pursuant to the Program Agreement,
PDS engaged Alliacense to negotiate MMP portfolio licenses and to pursue claims against violators of the MMP portfolio on behalf
of PDS, TPL, and the Company. The Program Agreement continued through the useful life of the MMP portfolio patents. Pursuant to
the TPL Agreement, we and TPL agreed to certain allocations of obligations in connection with the engagement of Alliacense. On
July 24, 2014, the Program Agreement was amended with PDS and Alliacense entering into the Amended Alliacense Services and Novation
Agreement (the “Novation Agreement”). Pursuant to the Novation Agreement certain performance goals and incentives were
established for Alliacense. The Novation Agreement also provided for the addition of a second licensing company, which was engaged
on October 10, 2014, to complement the MMP licensing commercialization. However, Alliacense fulfilled only a portion of its obligations
under the Novation Agreement associated with the deployment of the second licensing company and on May 11, 2015, Alliacense was
terminated by PDS.
On August 10, 2016, PDS entered into an agreement
with Alliacense and MMP Licensing, LLC to settle matters relating to Alliacense’s non-performance under terms of the Novation
Agreement. The August 10, 2016 agreement requires Alliacense to provide PDS’s second licensing company with certain materials
and to cooperate with reasonable discovery requests relating to infringement litigation currently pending in the U.S. District
Court for the Northern District of California. MMP Licensing, LLC will provide commercialization services to PDS for the MMP portfolio
with respect to certain companies. PDS and Alliacense have agreed to cause the arbitration between the parties to be dismissed
with prejudice. The August 10, 2016 agreement will expire on October 4, 2022. Terms of the settlement agreement required PDS to
pay Alliacense $84,000 within 24 hours after delivery of materials to PDS’s second licensing agent and to pay Alliacense
$84,000 out of subsequent recoveries. On August 11, 2016, PDS paid Alliacense $84,000.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Investment in Affiliated Company (continued)
During January 2013, TPL and Moore settled
their litigation. Terms of the settlement include the payment by PDS to Moore of a consulting fee of $250,000 for four years or
until the completion of all outstanding MMP litigation whichever comes first. Per terms of the agreement PDS paid Moore $150,000
on the settlement date and paid Moore $16,667 per month from August 2013 through January 2014 and will pay $20,833 per month beginning
February 2014 through January 2017. During both of the three months ended August 31, 2016 and 2015, PDS expensed $62,499 pursuant
to this commitment. These expenses are recorded in the accompanying PDS statements of operations presented below.
Based on our analysis of current authoritative
accounting guidance with respect to our investment in PDS, we continue to account for our investment in PDS under the equity method
of accounting, and accordingly have recorded our share of PDS’s net loss during the three months ended August 31, 2016 of
$55,395 as a decrease in our investment and we have recorded our share of PDS’s net income during the three months ended
August 31, 2015 of $322,259 as an increase in our investment. We received distributions of $16,000 from PDS during the three months
ended August 31, 2015 and we have recorded these distributions as a decrease in our investment.
We have recorded our share of PDS’s net
income and loss for the three months ended August 31, 2016 and 2015 as “Equity in earnings (loss) of affiliated company”
in the accompanying condensed consolidated statements of operations.
During the three months ended August 31, 2016
and 2015, PDS entered into licensing agreements with third parties, pursuant to which PDS received aggregate proceeds of $0 and
$1,050,000, respectively.
On March 20, 2013, TPL filed a petition under
Chapter 11 of the United States Bankruptcy Code. A Joint Plan of Reorganization (the “Joint Plan”) between TPL and
the creditor’s committee was confirmed by the Bankruptcy Court on February 11, 2015 with the entered confirmation order
becoming final on April 2, 2015. We have been appointed to the creditors’ committee and have been closely monitoring
the progress in this matter as it relates to our interest in PDS. In the event we are required to provide funding to PDS that is
not reciprocated by TPL, our ownership percentage in PDS will increase and we will have a controlling financial interest in PDS,
in which case, we will consolidate PDS in our condensed consolidated financial statements. If we determine that it is appropriate
to consolidate PDS, we would measure the assets, liabilities and noncontrolling interests of PDS at their fair values at the date
that we have the controlling financial interest.
PDS’s balance sheets at August 31, 2016
and May 31, 2016 and statements of operations for the three months ended August 31, 2016 and 2015 are as follows:
Balance Sheets
Assets:
|
|
August 31, 2016
|
|
May 31, 2016
|
|
|
(Unaudited)
|
|
(Audited)
|
Cash
|
|
$
|
592,035
|
|
|
$
|
741,971
|
|
Prepaid expenses
|
|
|
18,406
|
|
|
|
26,295
|
|
Total assets
|
|
$
|
610,441
|
|
|
$
|
768,266
|
|
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Investment in Affiliated Company (continued)
Liabilities and Members’ Equity:
|
|
August 31, 2016
|
|
May 31, 2016
|
|
|
(Unaudited)
|
|
(Audited)
|
Payables
|
|
$
|
380,516
|
|
|
$
|
427,553
|
|
Members’ equity
|
|
|
229,925
|
|
|
|
340,713
|
|
Total liabilities and members’ equity
|
|
$
|
610,441
|
|
|
$
|
768,266
|
|
Statements of Operations
|
|
Three Months Ended
August 31,
|
|
|
2016
|
|
2015
|
|
|
(Unaudited)
|
|
(Unaudited)
|
Revenues
|
|
$
|
–
|
|
|
$
|
1,050,000
|
|
Expenses
|
|
|
110,578
|
|
|
|
405,483
|
|
Income (loss) before provision for income taxes
|
|
|
(110,578
|
)
|
|
|
644,517
|
|
Provision for income taxes
|
|
|
210
|
|
|
|
–
|
|
Net income (loss)
|
|
$
|
(110,788
|
)
|
|
$
|
644,517
|
|
We review our investment in PDS to determine
whether events or changes in circumstances indicate that the carrying amount may not be recoverable. The primary factors we consider
in our determination are the financial condition, operating performance and near term prospects of PDS. If a decline in value
is deemed to be other than temporary, we would recognize an impairment loss.
4
.
Income Taxes
We have determined that it was more likely
than not that all of our deferred tax assets will not be realized in the future due to our continuing pre-tax and taxable losses.
As a result of this determination we have placed a full valuation allowance against our deferred tax assets. There have been no
changes to our determination during the current fiscal year.
5. Stockholders’ Equity
Share-based Compensation
Summary of Assumptions and Activity
The fair value of share-based awards to employees
and directors is calculated using the Black-Scholes option pricing model, even though this model was developed to estimate the
fair value of freely tradable, fully transferable options without vesting restrictions, which differ significantly from our stock
options.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Stockholders’ Equity (continued)
The Black-Scholes model also requires
subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the
calculated values. The expected term of options granted is derived from historical data on employee exercises and
post-vesting employment termination behavior. The risk-free rate selected to value any particular grant is based on the U.S.
Treasury rate that corresponds to the pricing term of the grant effective as of the date of the grant. The expected
volatility is based on the historical volatilities of our common stock. These factors could change in the future, affecting
the determination of share-based compensation expense in future periods.
A summary of option
activity as of August 31, 2016 and changes during the three months then ended, is presented below:
|
|
Shares
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Remaining
Contractual
Term
(Years)
|
|
Aggregate
Intrinsic
Value
|
Options outstanding at June 1, 2016
|
|
|
2,760,000
|
|
|
$
|
0.05
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
–
|
|
|
$
|
–
|
|
|
|
|
|
|
|
|
|
Options exercised
|
|
|
–
|
|
|
$
|
–
|
|
|
|
|
|
|
|
|
|
Options forfeited/expired
|
|
|
(160,000
|
)
|
|
$
|
0.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at August 31, 2016
|
|
|
2,600,000
|
|
|
$
|
0.06
|
|
|
|
3.12
|
|
|
$
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options vested and expected to vest at August 31, 2016
|
|
|
2,600,000
|
|
|
$
|
0.06
|
|
|
|
3.12
|
|
|
$
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at August 31, 2016
|
|
|
2,600,000
|
|
|
$
|
0.06
|
|
|
|
3.12
|
|
|
$
|
–
|
|
The aggregate intrinsic
value represents the differences in market price at the close of the quarter ($0.006 per share on August 31, 2016) and the exercise
price of outstanding, in-the-money options (those options with exercise prices below $0.006 per share) on August 31, 2016.
6. Commitments and Contingencies
Litigation
Patent Litigation
We, TPL, and PDS (collectively referred to
as “Plaintiffs”) are Plaintiffs in ongoing proceedings in the U.S. District Court for the Northern District of California
where the Plaintiffs allege infringement of the US 5,809,336 patent (the “‘336 patent”) by: Huawei Technologies
Co. Ltd., LG Electronics, Nintendo Co. Ltd., Samsung Electronics Co. Ltd., and ZTE Corporation. This litigation is proceeding in
front of District Court Judge Vince Chhabria.
These ongoing proceedings relate to the proceedings
filed by the Plaintiffs in February 2008 in the U.S. District Court for the Northern District of California alleging infringement
of the US 5,440,749 patent (the “‘749 patent”), the US 5,530,890 patent (the “‘890 patent”)
and the ‘336 patent against Amazon.com Inc., Barnes & Noble Inc., Garmin Ltd., Huawei Technologies Co. Ltd., Kyocera
Corporation, LG Electronics, Nintendo Co. Ltd., Novatel Wireless
Inc., Samsung Electronics Co. Ltd., Sierra Wireless Inc., and ZTE Corporation. We have settled with all defendants except those
named in the first paragraph to this footnote.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Commitments and Contingencies (continued)
On September 18, 2015, a Markman hearing was
held before U.S. Magistrate Judge Grewal and, on September 22, 2015, he issued a claim construction report and recommendation.
On September 25, 2015, as a result of the claim construction report and recommendation, Plaintiffs and defendants, with the exception
of Huawei Technologies Co. Ltd., (“Huawei”) agreed to stay all proceedings pending resolution of Plaintiffs’
objections to the claim construction report and recommendation. Plaintiffs further stipulated that, under the claim construction
provided by the report and recommendation, defendants’ products do not infringe the ‘336 patent, and, in the event
that the Court does not materially modify the claim construction, Plaintiffs and defendants ask that the Court enter a final judgment
of non-infringement. After Plaintiffs and Huawei filed opposing letter briefs with the Court, U.S. Magistrate Judge Grewal stayed
the action against Huawei pending resolution of Plaintiffs’ objections to the claim construction. On October 6, 2015, Plaintiffs
filed objections to the claim construction with District Court Judge Chhabria. Judge Chhabria rejected those objections on November
9, 2015. Based on that order, the parties stipulated to a judgment of non-infringement as to the ‘336 patent and such judgment
was entered on November 13, 2015.
On December 7, 2015, Plaintiffs filed notices
of appeal with the U.S. Federal Circuit appealing the district court’s claim construction. Plaintiffs filed their opening
appellate brief on March 10, 2016. Defendants filed their response brief on May 23, 2016, with Plaintiffs filing their reply brief
on June 23, 2016. The appeal is pending.
There was no material litigation or settlement
activity for the quarter ended August 31, 2016 and through the date of this filing.
PDS Arbitration - Alliacense Performance
In June 2015, our representative to the PDS
management committee filed with the Judicial Arbitration and Mediation Services (“JAMS”) a demand for arbitration pursuant
to Alliacense’s non-performance under terms of the Novation Agreement. The demand sought a declaration of the respective
rights and obligations of the parties under the Novation Agreement.
On August 10, 2016, PDS entered into an agreement
with Alliacense and MMP Licensing, LLC to settle matters relating to Alliacense’s non-performance under terms of the Novation
Agreement. The August 10, 2016 agreement requires Alliacense to provide PDS’s second licensing company with certain materials
and to cooperate with reasonable discovery requests relating to infringement litigation currently pending in the U.S. District
Court for the Northern District of California. MMP Licensing, LLC will provide commercialization services to PDS for the MMP portfolio
with respect to certain companies. The August 10, 2016 agreement will expire on October 4, 2022.
401(k) Plan
We have a retirement plan that complies
with Section 401(k) of the Internal Revenue Code. All employees are eligible to participate in the plan. We match 100% of
elective deferrals subject to a maximum of 4% of the participant’s eligible earnings. Our participants vest 33% per
year over a three year period in their matching contributions.
Our matching contributions during the three months ended August 31, 2016 and 2015 were $5,414 and $5,201, respectively.
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated
Financial Statements
Commitments and Contingencies (continued)
Guarantees and Indemnities
We have made certain guarantees and indemnities,
under which we may be required to make payments to a guaranteed or indemnified party. We indemnify our directors, officers, employees
and agents to the maximum extent permitted under the laws of the State of Delaware. The duration of the guarantees and indemnities
varies, and in many cases is indefinite. These guarantees and indemnities do not provide for any limitation of the maximum potential
future payments we could be obligated to make. Historically, we have not been obligated to make any payments for these obligations
and no liabilities have been recorded for these guarantees and indemnities in the accompanying condensed consolidated balance sheets.
Escrow Shares
On August 31, 2009 we gave notice to the former
shareholders of Crossflo and Union Bank of California (the “Escrow Agent”) under Section 2.5 of the Agreement and Plan
of Merger between us and Crossflo (the “Agreement”), outlining damages incurred by us in conjunction with the acquisition
of Crossflo, and seeking the return of 2,844,630 shares of our common stock held by the Escrow Agent. Subsequently, former
shareholders of Crossflo representing a majority of the escrowed shares responded in protest to our claim, delaying the release
of the escrowed shares until a formal resolution is reached. In the event we fail to prevail in our claim against the escrowed
shares, we may be obligated to deposit into escrow approximately $256,000 of cash consideration due to the decline in our average
stock price over the one year escrow period, calculated in accordance with the Section 2.5 of the Agreement. We have evaluated
the potential for loss regarding our claim and believe that it is probable that the resolution of this issue will not result in
a material obligation to the Company, although there is no assurance of this. Accordingly, we have not recorded a liability
for this matter.
7. Subsequent Events
We have evaluated subsequent events after the
balance sheet date and based on our evaluation, management has determined that no subsequent events have occurred that would require
recognition in the accompanying condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed
in the accompanying notes.